While Japan-based BioComo has been in existence for around a decade, it has so far concentrated on developing its academic research-derived platform technology based around TNFRSF signal activation, relying on relatively low-cost operations supported by relatives, friends and a small number of private investors.
Japan's BioComo Pursues Novel Ligand Approach To Immuno-Oncology
Avoids 4-1BB/OX-40 Toxicity Issues
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
